AIRSUPRA (albuterol sulfate and budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. Approved for asthma. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 2h ago
AIRSUPRA is a fixed-dose combination of albuterol sulfate (short-acting beta-2 agonist) and budesonide (inhaled corticosteroid) delivered as a metered-dose aerosol for asthma maintenance and rescue therapy. It combines rapid bronchodilation with anti-inflammatory effects through corticosteroid hormone receptor agonism. This dual-action inhaler addresses both acute symptoms and underlying airway inflammation in asthma patients.
Product is in peak commercial phase post-launch (2023 approval) with modest initial uptake; brand team likely in growth-to-stabilization mode managing early adoption.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
GRANITE: Airsupra Effectiveness in the Real World
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Worked on AIRSUPRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~4 years — strategic planning for patent cliff underway
AIRSUPRA offers career opportunities primarily in commercial roles given its peak lifecycle stage and recent 2023 launch; currently shows limited linked job postings but positions exist in field sales, brand management, and market access focused on asthma segment penetration. The product's safety profile (device/usage issues) creates demand for medical education and compliance roles to reduce adverse events and improve patient outcomes.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo